Suppr超能文献

相似文献

1
Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease.
Angew Chem Int Ed Engl. 2022 Dec 23;61(52):e202212378. doi: 10.1002/anie.202212378. Epub 2022 Nov 28.
3
A Patent Review on SARS Coronavirus Papain-Like Protease (PL ) Inhibitors.
ChemMedChem. 2023 Aug 15;18(16):e202300216. doi: 10.1002/cmdc.202300216. Epub 2023 Jun 15.
4
Structure-based design of SARS-CoV-2 papain-like protease inhibitors.
Eur J Med Chem. 2024 Jan 15;264:116011. doi: 10.1016/j.ejmech.2023.116011. Epub 2023 Dec 5.
6
Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships.
Bioorg Med Chem. 2024 Nov 1;113:117909. doi: 10.1016/j.bmc.2024.117909. Epub 2024 Sep 11.
7
A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease.
Cell Rep. 2021 Sep 28;36(13):109754. doi: 10.1016/j.celrep.2021.109754. Epub 2021 Sep 8.
8
Drug Repurposing for the SARS-CoV-2 Papain-Like Protease.
ChemMedChem. 2022 Jan 5;17(1):e202100455. doi: 10.1002/cmdc.202100455. Epub 2021 Oct 12.
9
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
ChemMedChem. 2022 May 4;17(9):e202200016. doi: 10.1002/cmdc.202200016. Epub 2022 Feb 17.

引用本文的文献

1
Covalent DNA-Encoded Library Workflow Drives Discovery of SARS-CoV-2 Nonstructural Protein Inhibitors.
J Am Chem Soc. 2024 Dec 11;146(49):33983-33996. doi: 10.1021/jacs.4c12992. Epub 2024 Nov 22.
2
Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors.
J Med Chem. 2024 Nov 28;67(22):20399-20420. doi: 10.1021/acs.jmedchem.4c01872. Epub 2024 Nov 5.
3
Native Mass Spectrometry Reveals Binding Interactions of SARS-CoV-2 PLpro with Inhibitors and Cellular Targets.
ACS Infect Dis. 2024 Oct 11;10(10):3597-3606. doi: 10.1021/acsinfecdis.4c00444. Epub 2024 Sep 20.
5
Structure-based design of SARS-CoV-2 papain-like protease inhibitors.
Eur J Med Chem. 2024 Jan 15;264:116011. doi: 10.1016/j.ejmech.2023.116011. Epub 2023 Dec 5.
8
Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection.
Front Pharmacol. 2022 Nov 11;13:1035969. doi: 10.3389/fphar.2022.1035969. eCollection 2022.

本文引用的文献

1
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
2
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
J Med Chem. 2022 Feb 24;65(4):2940-2955. doi: 10.1021/acs.jmedchem.1c01307. Epub 2021 Oct 19.
3
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection.
Nat Immunol. 2021 Nov;22(11):1416-1427. doi: 10.1038/s41590-021-01035-8. Epub 2021 Oct 18.
5
Drug Repurposing for the SARS-CoV-2 Papain-Like Protease.
ChemMedChem. 2022 Jan 5;17(1):e202100455. doi: 10.1002/cmdc.202100455. Epub 2021 Oct 12.
8
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
Cell Chem Biol. 2021 Jun 17;28(6):855-865.e9. doi: 10.1016/j.chembiol.2021.04.020. Epub 2021 Apr 27.
9
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Protein Cell. 2021 Nov;12(11):877-888. doi: 10.1007/s13238-021-00836-9. Epub 2021 Apr 17.
10
ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity.
Nat Microbiol. 2021 Apr;6(4):467-478. doi: 10.1038/s41564-021-00884-1. Epub 2021 Mar 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验